panbronchiolitis%20-%20diffuse
PANBRONCHIOLITIS - DIFFUSE
Diffuse panbronchiolitis is an inflammatory disease affecting the respiratory bronchioles.
It causes progressive suppurative and obstructive respiratory disease.
This is an idiopathic disease which is primarily found in Japan, Korea and China.
Predisposition to the disease may be genetically-related but environmental factors should also be considered.
Failure to treat diffuse panbronchiolitis can lead to development of bronchiectasis, progressive failure and death.

Panbronchiolitis%20-%20diffuse Signs and Symptoms

Introduction

  • This is an idiopathic disease which is primarily found in Japan, Korea & China
  • Predisposition to the disease may be genetically-related but environmental factors should also be considered
  • Failure to treat diffuse panbronchiolitis (DPB) leads to development of widespread bronchiectasis, progressive respiratory failure & death

Epidemiology

  • More common in 2nd-5th decade of life
  • Not related to smoking & exposure to toxic fumes
  • High incidence in Asian countries (Japan, Korea, Taiwan, Malaysia, China, Thailand, Singapore)

Definition

  • Inflammatory disease affecting the respiratory bronchioles
  • Causes progressive suppurative & obstructive respiratory disease

Signs and Symptoms

  • Chronic paranasal sinusitis (>80%)
  • Productive cough which usually occurs in the 2nd-5th decade of life
  • Wheezing
  • Dyspnea on exertion
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
21 Nov 2020
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
Elvira Manzano, 12 May 2020
After months of work disruption, profound worrying, social distancing, and isolation, SARS-CoV-2* still rages on, unyielding to human interventions.
Rachel Soon, 05 Dec 2020

The Malaysian National Immunisation Programme (NIP) will now include a hexavalent combination DTaP-IPV-HiB-HepB vaccine and a pneumococcal vaccine.

Roshini Claire Anthony, 18 Jun 2020

Endorsement of unproven COVID-19 treatments by high-profile public figures led to a drastic increase in the search and purchase of said treatments in the US, according to a research letter published in JAMA.